July 13th, 2018 – Adastra Labs Holdings Ltd. (“Adastra” or the “Company”) announces Adastra Labs hires Donald Dinsmore, MScPB as Alternate Quality Assurance Person for its lower mainland facility. CEO Andy Hale stated, “With a Masters in Plant Biochemistry and hands on operational experience in the cannabis cultivation industry, Donald brings a perfect set of skills to help Adastra Labs become a cannabis extracts and concentrates leader in Canada.”
Mr. Dinsmore is a professional plant biochemist with a background working with successful research groups. He was born and raised in Calgary, Alberta where he attended the University of Calgary. During his undergraduate in Biochemistry degree he completed two research projects; one, studying the effects of heavy metals on cell membranes and the second utilizing site-directed mutagenesis to investigate the reaction mechanism of enzymes involved in opium poppy secondary metabolism. After earning his Bachelor’s degree, he completed a Master’s degree in Plant Biochemistry where he studied opium poppy metabolism and genomics under the tutelage of Dr. Peter Facchini. As part of the Genome Canada Project, Mr. Dinsmore was responsible for the analysis and creation of LC-MS/MS metabolomic databases for twenty unique alkaloid producing species. In addition, he employed a variety of genetic and biochemical techniques to identify novel genes from opium poppy. He also helped to train undergraduate students and guide their honours projects. An opportunity at Heart Rock Mountain Farms in Mendocino County, California began his career in the cannabis industry. He developed a ground-up understanding of organic cannabis farming and processing. In his time there, he moved up from farm labourer to operations manager, reporting to the head grower, where he helped lead a dynamic team to a record-breaking harvest.
For further information, please contact:
Andy Hale, CEO
About Adastra Labs Holdings Ltd.
In Canada, Adastra (through its wholly owned subsidiary, Adastra Labs Inc.) is in the application process to become a Standard Processor under the Cannabis Act administered by Health Canada, with a licence to produce cannabis extracts. This licence will further enable Adastra and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licensed entities and internationally in jurisdictions where medical cannabis extraction products are legal.
The Company’s operations include a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing by late 2019, from which it expects to produce significant amounts of cannabis oil and/or hemp oil for the Canadian wholesale medical and recreational markets.
The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, Adastra will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: Adastra’s expectations concerning an increase in its production capacity. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Adastra assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: Adastra Labs Holdings Ltd.